Background: WHO 2008 classification of Non Hodgkin Lymphoma (NHL) has been introduced andgot consensus internationally. However, studies on NHL according to WHO 2008 classification are limitedin Vietnam. In terms of treatment, the R-CHOP regimen is still the most commonly used regimen for thetreatment of moderate or high grade malignant lymphoma tumors. However, its effectiveness on eachtype has not been specifically studied. Purpose of this research is to evaluate of clinical and subclinicalcharacteristics of NHL patients according to the 2008 WHO classification on lymphoid neoplasms and toevaluate preliminary effective of diffuse large B cell lymphoma (DLBCL) patients with R-CHOP regimen.Materials and methods: A prospective descriptive study was conducted on 48 patients diagnosed withNHL undergoing treatment at the Hue University Hospital from July 2019 and Hue Central Hospital fromApril 2020 to present.Results: The mean age was 52.4 years, male/female ratio = 1.3/1, the most common primary tumorsite was lymph nodes with 54.3%. Stage IV was found in 37.5% of all cases. DLBCL was the most commontype, accounted for 58.3%, whereas marginal zone lymphoma had the lowest incidence (2.1%). Accordingto the International Prognostic Index (IPI), low risk, low-intermediate risk, high-intermediate risk, high riskgroup were 43.6%
25.0%
18.8%
12.6% respectively. 34.8% patients responsed completely after 3 cyclesand after 6 – 8 cycles, 58.8% patients achieved complete response. Grade III, IV neutropenia, grade I, IIperipheral neuropathy and grade I, II thrompocytopenia were the most common side effect observed.Conclusions: DLBCL is the most common Non Hodgkin Lymphoma. R-CHOP regimen has a goodresponse after 6-8 cycles in DLBCL diseases and is well tolerated that the adverse events are mostly ableto control effectively.